Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement, MSA, with Telix IsoTherapeutics Group. This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium Obisbemeda. Key highlights of the agreement: Focus on the production of key radionuclide intermediate aluminum perrhenate and the final processing of cGMP Re-186; Enables expanded, scalable, just-in-time manufacturing to support overall supply chain
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PSTV:
- Plus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trial
- Plus Therapeutics to present FORESEE clinical trial summary
- Plus Therapeutics subsidiary to present data on CNSide CSF Assay Platform
- Plus Therapeutics Advances Radiotherapeutics in Q3 2024
- Plus Therapeutics reports Q3 EPS (37c), consensus (56c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
